At the time of writing, Alnylam Pharmaceuticals Inc [ALNY] stock is trading at $287.01, up 2.25%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ALNY shares have gain 3.49% over the last week, with a monthly amount glided 20.87%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] stock has seen the most recent analyst activity on August 16, 2024, when Goldman upgraded its rating to a Buy and also boosted its price target to $370 from $198. Previously, Goldman downgraded its rating to Neutral on February 16, 2024, and kept the price target unchanged to $173. On February 15, 2024, Wolfe Research initiated with a Peer Perform rating. Wells Fargo started tracking the stock assigning a Equal Weight rating and suggested a price target of $171 on December 08, 2023. Wells Fargo initiated its recommendation with a Equal Weight. Oppenheimer downgraded its rating to Perform for this stock on October 11, 2023. In a note dated September 29, 2023, Raymond James initiated an Outperform rating and provided a target price of $208 on this stock.
For the past year, the stock price of Alnylam Pharmaceuticals Inc fluctuated between $141.98 and $286.00. Currently, Wall Street analysts expect the stock to reach $250.16 within the next 12 months. Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] shares were valued at $287.01 at the most recent close of the market. An investor can expect a potential drop of -12.84% based on the average ALNY price forecast.
Analyzing the ALNY fundamentals
According to Alnylam Pharmaceuticals Inc [NASDAQ:ALNY], the company’s sales were 2.34B for trailing twelve months, which represents an 107.00% jump. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at 0.04%, Pretax Profit Margin comes in at -0.03%, and Net Profit Margin reading is -0.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is 0.48 and Total Capital is 0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -804.98.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 281.76 points at the first support level, and at 276.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 289.90, and for the 2nd resistance point, it is at 292.80.
Ratios To Look Out For
It is important to note that Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] has a current ratio of 3.01. In addition, the Quick Ratio stands at 2.93 and the Cash Ratio stands at 0.92. Considering the valuation of this stock, the price to sales ratio is 15.72.
Transactions by insiders
Recent insider trading involved Greenstreet Yvonne, Chief Executive Officer, that happened on Aug 20 ’24 when 15000.0 shares were sold. Officer, Greenstreet Yvonne completed a deal on Aug 20 ’24 to buy 15000.0 shares. Meanwhile, CSO & EVP, Head of Research Fitzgerald Kevin Joseph sold 22025.0 shares on Aug 12 ’24.
